The fatty acid synthase inhibitor triclosan: Repurposing an anti-microbial agent for targeting prostate cancer

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9362-9381

  Sadowski, Martin C ^a   Pouwer, Rebecca H ^b   Gunter, Jennifer H ^a   Lubik, Amy A ^a,c   Quinn, Ronald J ^b   Nelson, Colleen C ^a,c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AMPK; C75; Fatty acid synthase; Lipid metabolism; Orlistat; Prostate cancer; Triclosan

Indexed keywords

C 75; ENZYME INHIBITOR; FATTY ACID SYNTHASE; TETRAHYDROLIPSTATIN; TRICLOSAN; UNCLASSIFIED DRUG; 4-METHYLENE-2-OCTYL-5-OXOFURAN-3-CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE INHIBITOR; GAMMA BUTYROLACTONE; LACTONE; TOPICAL ANTIINFECTIVE AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CATALYSIS; CELL CYCLE REGULATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; HOMEOSTASIS; LIPID METABOLISM; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG REPOSITIONING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; MALE; MOUSE; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

3T3 CELLS; 4-BUTYROLACTONE; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG REPOSITIONING; FATTY ACID SYNTHASE, TYPE I; FATTY ACID SYNTHESIS INHIBITORS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LACTONES; LIPID METABOLISM; MALE; MICE; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TRICLOSAN;

EID: 84910026168     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2433     Document Type: Article

References (51)

1. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 1989; 28(11):4523-4530.
2. Smith S, Witkowski A and Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003; 42(4):289-317.
3. Brusselmans K and Swinnen J. (2009). The Lipogenic Switch in Cancer. Mitochondria and Cancer: Springer New York), pp. 39-59.
4. Lupu R and Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol. 2006; 7(6):483-493.
5. Rendina AR and Cheng D. Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates. Biochem J. 2005; 388(Pt 3):895-903.
6. Wang X and Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun. 2001; 288(5):1200-1206.
7. Takahiro T, Shinichi K and Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res. 2003; 9(6):2204-2212.
8. Liu B, Wang Y, Fillgrove KL and Anderson VE. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol. 2002; 49(3):187-193.
9. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A. 2000; 97(7):3450-3454.
10. Thupari JN, Kim EK, Moran TH, Ronnett GV and Kuhajda FP. Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am J Physiol Endocrinol Metab. 2004; 287(1):E97-E104.
11. Zhou W, Han WF, Landree LE, Thupari JN, Pinn ML, Bililign T, Kim EK, Vadlamudi A, Medghalchi SM, El Meskini R, Ronnett GV, Townsend CA and Kuhajda FP. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res. 2007; 67(7):2964-2971.
12. Lambert JD and Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res. 2003; 523-524:201-208.
13. McNeely W and Benfield P. Orlistat. Drugs. 1998; 56(2):241-249; discussion 250.
14. McMurry LM, Oethinger M and Levy SB. Triclosan targets lipid synthesis. Nature. 1998; 394(6693):531-532.
15. Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ and Taylor IW. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry. 1999; 38(38):12514-12525.
16. Deepa PR, Vandhana S, Jayanthi U and Krishnakumar S. Therapeutic and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells. Basic Clin Pharmacol Toxicol. 2012; 110(6):494-503.
17. Honkisz E, Zieba-Przybylska D and Wojtowicz AK. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. Reprod Toxicol. 2012; 34(3):385-392.
18. Schmid B, Rippmann JF, Tadayyon M and Hamilton BS. Inhibition of fatty acid synthase prevents preadipocyte differentiation. Biochem Biophys Res Commun. 2005; 328(4):1073-1082.
19. Lu S and Archer MC. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis. 2005; 26(1):153-157.
20. Kumar V, Chakraborty A, Kural MR and Roy P. Alteration of testicular steroidogenesis and histopathology of reproductive system in male rats treated with triclosan. Reprod Toxicol. 2009; 27(2):177-185.
21. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
22. Bhargava HN and Leonard PA. Triclosan: applications and safety. Am J Infect Control. 1996; 24(3):209-218.
23. McCune SA and Harris RA. Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J Biol Chem. 1979; 254(20):10095-10101.
24. Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T and Suzuki T. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2000; 48(5):613-622.
25. Flavin R, Zadra G and Loda M. Metabolic alterations and targeted therapies in prostate cancer. The Journal of pathology. 2011; 223(2):283-294.
26. Huang WC, Zhau HE and Chung LW. Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem. 2010; 285(11):7947-7956.
27. Huang WC, Li X, Liu J, Lin J and Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Molecular cancer research: MCR. 2012; 10(1):133-142.
28. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-1174.
29. Kridel SJ, Axelrod F, Rozenkrantz N and Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004; 64(6):2070-2075.
30. Mason P, Liang B, Li L, Fremgen T, Murphy E, Quinn A, Madden SL, Biemann HP, Wang B, Cohen A, Komarnitsky S, Jancsics K, Hirth B, Cooper CG, Lee E, Wilson S, et al. SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One. 2012; 7(3):e33823.
31. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA and Kuhajda FP. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000; 60(2):213-218.
32. Winstead MV, Balsinde J and Dennis EA. Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta. 2000; 1488(1-2):28-39.
33. Kurumbail RG, Kiefer JR and Marnett LJ. Cyclooxygenase enzymes: catalysis and inhibition. Current opinion in structural biology. 2001; 11(6):752-760.
34. Bennett MK, Lopez JM, Sanchez HB and Osborne TF. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J Biol Chem. 1995; 270(43):25578-25583.
35. Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, Lee SH, Powles M, Ellsworth KP, Lassman ME, Miller C, Myers RW, Tota MR, Zhang BB and Li C. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci U S A. 2011; 108(13):5378-5383.
36. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF and Pizer ES. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001; 61(4):1493-1499.
37. Ho TS, Ho YP, Wong WY, Chi-Ming Chiu L, Wong YS and Eng-Choon Ooi V. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother. 2007; 61(9):578-587.
38. Knowles LM, Axelrod F, Browne CD and Smith JW. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem. 2004; 279(29):30540-30545.
39. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W and Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology. 1996; 137(10):4468-4474.
40. Swinnen JV, Esquenet M, Goossens K, Heyns W and Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 1997; 57(6):1086-1090.
41. Kwok AC and Wong JT. Lipid biosynthesis and its coordination with cell cycle progression. Plant Cell Physiol. 2005; 46(12):1973-1986.
42. Greenspan P, Mayer EP and Fowler SD. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol. 1985; 100(3):965-973.
43. Rodricks JV, Swenberg JA, Borzelleca JF, Maronpot RR and Shipp AM. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Critical reviews in toxicology. 2010; 40(5):422-484.
44. Pandey PR, Liu W, Xing F, Fukuda K and Watabe K. Anti-cancer drugs targeting fatty acid synthase (FAS). Recent patents on anti-cancer drug discovery. 2012; 7(2):185-197.
45. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV and Kuhajda FP. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003; 63(21):7330-7337.
46. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N and Schulze A. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012; 2(4):328-343.
47. Hardie DG, Ross FA and Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature reviews Molecular cell biology. 2012; 13(4):251-262.
48. Gubern A, Barcelo-Torns M, Casas J, Barneda D, Masgrau R, Picatoste F, Balsinde J, Balboa MA and Claro E. Lipid droplet biogenesis induced by stress involves triacylglycerol synthesis that depends on group VIA phospholipase A2. J Biol Chem. 2009; 284(9):5697-5708.
49. Gunter JH, Sarkar PL, Lubik AA and Nelson CC. New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. International journal of cell biology. 2013; 2013:834684.
50. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N and Loda M. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO molecular medicine. 2014.
51. Sadowski M, Mawson A, Baker R and Sarcevic B. Cdc34 C-terminal tail phosphorylation regulates Skp1/cullin/F-box (SCF)-mediated ubiquitination and cell cycle progression. Biochem J. 2007; 405(3):569-581.